Department of Global Health, University of Washington, Seattle, WA; Division of Surgical Outcomes and Precision Medicine Research, Department of Surgery, University of Minnesota Medical School, Minneapolis, MN; Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington School of Medicine, Seattle, WA.
CONRAD, Eastern Virginia Medical School, Norfolk, VA.
Am J Obstet Gynecol. 2022 Feb;226(2):225.e1-225.e15. doi: 10.1016/j.ajog.2021.09.018. Epub 2021 Sep 22.
Bacterial vaginosis-a condition defined by a shift from Lactobacillus dominance to a polymicrobial, anaerobic bacterial community-increases the risk of acquiring sexually transmitted infections and other complications of the female reproductive tract. Antibiotic treatment frequently fails to return the microbiome to an optimal Lactobacillus-dominated state. No criteria currently exist to identify the patients likely to experience treatment failure.
We sought to identify the pretreatment community signatures associated with treatment failure through 16S ribosomal RNA gene analysis.
Twenty-eight women who were enrolled in an oral metronidazole treatment trial of bacterial vaginosis were studied. Cervicovaginal lavage samples were collected before metronidazole treatment and at 7 and 30 days posttreatment. Cervicovaginal lavage DNA was amplified and sequenced using a paired-end, V4 region 2×150 MiSeq run.
Of the 28 women, 25% failed to clear bacterial vaginosis; 35.7% demonstrated a transient clearance, shifting to community-type 2 (Lactobacillus iners dominant) at visit 2 only; 7.1% demonstrated a delayed clearance, reaching community-type 2 at the final visit only; and 32.1% of patients experienced sustained bacterial vaginosis clearance. Examination of the community composition and structure demonstrated that both the richness and the evenness were significantly lower for the women who experienced sustained clearance, whereas the women who failed to clear bacterial vaginosis possessed the highest median levels of richness, evenness, and diversity pretreatment. Soluble immune factors in the lower reproductive tract improved significantly following a shift from community-type 4 to a Lactobacillus-dominant microbiome, with the samples categorized as community-type 2 possessing significantly higher levels of secretory leukocyte protease inhibitor, growth-regulated alpha protein, and macrophage inflammatory protein-3 and significantly lower levels of intercellular adhesion molecule-1. Although the shifts to Lactobacillus dominance improved the markers of mucosal tissue health, these gains were only temporary among the women who experienced recurrence.
Assemblies of highly diverse microbiota are associated with the enhanced resilience of bacterial vaginosis to standard metronidazole treatment. These communities may be foundational to treatment resistance or simply an indication of a well-established community made possible by canonical biofilm-forming taxa. Future studies must target the transcriptional activity of these communities under the pressure of antibiotic treatment to resolve the mechanisms of their resistance.
细菌性阴道病是一种由乳杆菌优势向多微生物、厌氧细菌群落转变的病症,会增加获得性传播感染和女性生殖道其他并发症的风险。抗生素治疗常常无法使微生物组恢复到最佳的乳杆菌主导状态。目前尚无标准来确定哪些患者可能会出现治疗失败。
我们试图通过 16S 核糖体 RNA 基因分析来确定与治疗失败相关的预处理群落特征。
对 28 名参加细菌性阴道病口服甲硝唑治疗试验的女性进行了研究。在甲硝唑治疗前和治疗后 7 天和 30 天采集宫颈阴道灌洗液样本。使用配对末端、V4 区 2×150 MiSeq 运行对宫颈阴道灌洗液 DNA 进行扩增和测序。
在 28 名女性中,25%的女性未能清除细菌性阴道病;35.7%的女性仅在第二次就诊时表现出短暂的清除,转变为群落型 2(以乳杆菌不占优势);7.1%的女性表现出延迟清除,仅在最后一次就诊时达到群落型 2;32.1%的患者经历了持续的细菌性阴道病清除。对群落组成和结构的检查表明,持续清除的女性的丰富度和均匀度明显较低,而未能清除细菌性阴道病的女性在治疗前具有最高的丰富度、均匀度和多样性中位数水平。从群落型 4 转变为乳杆菌主导的微生物组后,下生殖道的可溶性免疫因子显著改善,归类为群落型 2 的样本具有显著更高水平的分泌白细胞蛋白酶抑制剂、生长调节α蛋白和巨噬细胞炎症蛋白-3,以及显著更低水平的细胞间黏附分子-1。虽然向乳杆菌主导地位的转变改善了黏膜组织健康的标志物,但这些改善在经历复发的女性中只是暂时的。
高度多样化的微生物群集与细菌性阴道病对标准甲硝唑治疗的增强抵抗力相关。这些群落可能是治疗耐药的基础,或者仅仅是由经典生物膜形成分类群所形成的成熟群落的指示。未来的研究必须针对这些群落在抗生素治疗压力下的转录活性,以解决其耐药机制。